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Abstract
Background: The prevalence of diabetes among adults in Mexico has increased markedly from 6.7 % in 1994 to
14.7 % in 2015. Although the main diabetic complications can be prevented or delayed with timely and effective
primary care, a high percentage of diabetic patients have developed them imposing an important preventable
burden on Mexican society and on the health system. This paper estimates the financial and health burden caused
by potentially preventable hospitalisations due to diabetic complications in hospitals operated by the largest social
security institution in Latin America, the Mexican Institute of Social Security (IMSS), in the period 2007–2014.
Methods: Hospitalisations in IMSS hospitals whose main cause was a diabetic complication were identified. The
financial burden was estimated using IMSS diagnostic-related groups. To estimate the health burden, DALYs were
computed under the assumption that patients would not have experienced complications if they had received
timely and effective primary care.
Results: A total of 322,977 hospitalisations due to five diabetic complications were identified during the period
studied, of which hospitalisations due to kidney failure and diabetic foot represent 78 %. The financial burden
increased by 8.4 % in real terms between 2007 and 2014. However, when measured as cost per IMSS affiliate, it
decreased by 11.3 %. The health burden had an overall decrease of 13.6 % and the associated DALYs in 2014
reached 103,688.
Conclusions: Resources used for the hospital treatment of diabetic complications are then not available for other
health care interventions. In order to prevent these hospitalisations more resources might need to be invested in
primary care; the first step could be to consider the financial burden of these hospitalisations as a potential target
for switching resources from hospital care to primary care services. However, more evidence of the effectiveness
of different primary care interventions is needed to know how much of the burden could be prevented by better
primary care.
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Background
People with diabetes are at higher risk of developing dis-
abling and life-threatening health problems than people
without diabetes [1]. However, diabetes complications
can be prevented or delayed by maintaining good con-
trol of blood glucose, blood pressure and cholesterol
levels [1]. Many complications can be detected at an
early stage allowing treatment that can prevent the con-
dition becoming more serious and more costly [1]. The
high economic cost and the effect on the quality of life
of the population with diabetic complications impose an
important preventable burden on Mexican society and
on its health system [2]. The resources that are allocated
to the treatment of these complications (specifically hos-
pitalisations) are then not available for other health care
interventions. This paper estimates the financial and
health burden caused by potentially preventable hospi-
talisations due to diabetic complications in hospitals
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operated by the Mexican Institute of Social Security
(IMSS) in the period 2007–2014.
The percentage of the Mexican population living with
diabetes has increased markedly during recent decades.
In 1994, the prevalence of diabetes was 6.7 %, in 2000 it
grew to 7.5 % and in 2006 it reached 14.4 % [3]. The
overall prevalence of diabetes among adults aged 20–79
in Mexico in 2015 was 14.7 % and Mexico ranks sixth
worldwide for number of adults with diabetes (11.5 million
adults) with 3.9 million having undiagnosed diabetes [1].
According to Hernández-Ávila et al. (2013), 14.3 % of
the diabetic population in Mexico do not receive medical
treatment; moreover, in 2012 only 25 % of those diagnosed
were under metabolic control [4, 5]. The poor control of
diabetes has resulted in a high number of complications:
46.9 % of diabetic patients have a diagnosis of hyperten-
sion; 47.6 % have decreased vision; 13.9 % present retinal
damage; 6.6 % have lost their sight; 1.4 % receive haemo-
dialysis because of kidney failure; 2 % have suffered an
amputation and 2.8 % a cardiac arrest [5].
Diabetes is considered to be an ambulatory care sensi-
tive condition where early diagnosis and the follow-up
and monitoring of the condition can prevent exacerbation
of the disease which may lead to hospitalisation [6, 7].
Moreover, timely detection and good control of diabetes is
central to preventing diabetes progression and the devel-
opment of vascular complications [8]. Thus, the low
compliance with national diabetes control guidelines
(with only 52.7 % of diabetics obtaining a blood glucose
test, 14.6 % having their feet checked, and 9.6 % obtaining
an HbA1c test at the time of a regular physician visit) and
the high prevalence of diabetic complications suggest that
the Mexican primary care system as a whole may have
been overwhelmed by the diabetes epidemic [9–11].
The economic burden of diabetes in Mexico has been
analysed in several studies [3, 10, 12, 13]. Barraza-
Lloréns et al. (2015) estimated that in 2013 this burden,
including direct and indirect costs, was MXN$362,860
million accounting for 2.25 % of GDP. Direct costs were
estimated as MXN$179,495 million of which medical
care for the main diabetic complications represented
87 % [13]. Lugo-Palacios and Cairns (2016) show that
during 2001–2011 hospitalisation costs due to five diabetic
complications (kidney failure, retinopathy, neuropathy,
diabetic foot and amputation) increased by 125 %, in
general hospitals run by state health ministries, reaching
MXN$1,284.7 million in 2011 [2].
The health burden of diabetes in 2013 was estimated
to be 1,903,650 Disability-Adjusted Life Years (DALYs)
[14]. The health burden of hospitalisations due to diabetic
complications in general hospitals run by state health
ministries, accounted for 4.2 % of total DALYs associated
with diabetes in Mexico in 2010 and increased over the
period 2001–2011 by 112 % [2].
The financial cost of the hospital care provided can be
considered to be a proxy for the direct economic burden
of preventable hospitalisations. The health burden of
these hospitalisations can be estimated by the disability
suffered by patients with diabetic complications that
would not have been incurred if they had received appro-
priate primary care [2]. Whether these hospitalisations are
related to low-quality primary care, non-adherence to the
recommended treatments or to easy access to secondary
care through the emergency department they are, in
principle, preventable at the primary level, and their
presence suggests a failure of the primary care system,
which includes providers, patients and health author-
ities, not only the primary care team.
This paper analyses the financial and health burden
imposed by potentially preventable diabetic hospitalisa-
tions in IMSS hospitals. IMSS is the largest social se-
curity institution in Latin America providing health
care and other social security services to more than 59
million beneficiaries from the ordinary scheme, (ac-
counting for 49 % of the Mexican population). IMSS has
recently designed and implemented a strategic plan that
is intended to improve quality, health outcomes, and
patient satisfaction while assuring IMSS’s financial sus-
tainability in the short, medium, and long run [15].
Assessing the effect of these strategies on diabetic com-
plications is, however, beyond the scope of this study.
The objective of this paper is to extend the work done
by Lugo-Palacios and Cairns [2] to the IMSS case by es-
timating the magnitude and trend of the financial and
health burden associated with potentially preventable
diabetic hospitalisations while avoiding double-counting
of the health burden due to multiple discharges.
Methods
This analysis follows the methodology proposed by Lugo-
Palacios and Cairns [2] and uses hospital discharge data
for the period 2007–2014 from six types of IMSS general
hospitals: sub-zone general hospitals; zone general hospi-
tals; regional general hospitals; and sub-zone, zone and re-
gional hospitals with a primary care unit. Data on medical
procedures, main and secondary diagnoses, as well as the
code of the unit where the patient is registered to receive
primary care, among other variables, were recorded for
each discharge [16]. Importantly, multiple discharges for
the same patient can be identified. IMSS has a well-
structured information system for recording every single
hospital discharge across medical units which ensures the
quality of the recorded data [17].
Hospitalisations of patients 20 years or older due to
five complications of diabetes (retinopathy, kidney fail-
ure, neuropathy, diabetic foot and diabetic amputations)
were identified through the ICD-10 code of the main
diagnosis in each case. Amputations where the main
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hospitalisation diagnosis was any of the diabetic codes
considered in this study, were classified as diabetic am-
putations and included in the analysis.
To estimate the financial cost of preventable diabetic
hospitalisations in IMSS hospitals this study uses the
IMSS Diagnostic-Related Group (DRG) system [18].
When the ICD-10 code could be assigned to more than
one DRG, the decision on which DRG to use was based
on the DRG that included all the ICD-10 codes related
to the complication. With the exception of diabetic am-
putations, the DRG costs were taken from the IMSS
Medical-Economic Forms where cost estimates for each
DRG are reported. Since diabetic amputations are de-
fined as those hospitalisations where the main diagnosis
was any diabetic ICD-10 code where the patient suffered
an amputation, only the cost of the surgical procedure
was considered as this intervention represents additional
costs not previously accounted for in the DRG cost. The
latter cost was obtained from the inter-institutional max-
imum referral tariffs [19]. Table 1 shows the DRG classi-
fication and costs for all the ICD-10 codes considered in
this analysis. It is worth noting that the codes considered
for all the complications analysed (including kidney fail-
ure) are only those related to diabetes. IMSS-DRG cost
data are only available for 2013, thus, it was necessary to
assume that IMSS-DRG costs only changed due to infla-
tion during the study period.
The estimation of the health burden assumes that pa-
tients would not have experienced complications if they
had received appropriate primary care and computes the
associated DALYs. Disability weights for diabetic foot,
neuropathy, kidney failure – stage IV, amputation of toe,
amputation of one leg, and amputation of both legs were
taken from the Global Burden of Disease Study 2010
[20]. The weight for retinopathy-blindness was taken
from the Global Burden of Disease 2004 Update, since
the 2010 version did not report a weight for this condi-
tion [21]. Due to lack of detail concerning the severity of
the condition of hospitalised patients (e.g. degree of kid-
ney failure or seriousness of retinopathy) and the ab-
sence of disability weights for different severity levels,
only one level of disability (equal to the available weight
in each case) is considered for patients whose main hos-
pitalisation diagnosis was kidney failure, retinopathy,
neuropathy and diabetic foot. WHO data on the life ex-
pectancy at age with the lowest mortality observed
worldwide are used to compute the Years of Life Lost
(YLL) and Years Lived with Disability (YLD) [22, 23].
Some hospitalised patients whose main diagnosis was
kidney failure, neuropathy, retinopathy and diabetic foot
also suffered amputations. Hence, to avoid double
counting of deaths while computing YLL it was neces-
sary to define the variable “net amputation” indicating
those diabetic amputations in which the main cause of
hospitalisation was none of the other complications;
therefore, amputation YLL are based on net amputa-
tions. However, when computing YLD the total number
of people suffering amputations was used, since amputa-
tions will contribute to their disability; in this case, pa-
tients with diabetic foot without amputations (net
diabetic foot) were used to compute diabetic foot YLD.
Results
Table 2 shows the composition of hospitalisations due to
diabetic complications in IMSS general hospitals during
2007–2014. A total of 322,977 hospitalisations met the
described criteria, of which hospitalisations due to kid-
ney failure and diabetic foot represent 78 %. Hospitalisa-
tions due to diabetic complications increased by 10.3 %
over this period. Total hospitalisations caused by dia-
betic complications per 10,000 IMSS affiliates (not
shown), decreased by 9.8 % from 7.91 in 2007 to 7.13 in
2014, reaching a maximum (8.15) in 2008 and a mini-
mum (6.96) in 2013.
From Table 2 it can also be observed that the per-
centage of multiple admissions/discharges for the same
Table 1 Diabetic ICD-10 codes and DRG classification
ICD-10 of diabetic complications DRG IMSS DRG 2013 Cost (MXN)
Kidney failure E10.2, E11.2, E12.2, E13.2, E14.2 698 – Other kidney and urinary tract diagnostics
with major complications
71 066
Retinopathy E10.3, E11.3, E12.3, E13.3, E14.3 125 – Other eye disorders 22 820
Neuropathy E10.4, E11.4, E12.4, E13.4, E14.4 074 – Cranial and peripheral nerve disorders with
no major complications
37 494
Diabetic foot E10.5, E11.5, E12.5, E13.5, E14.5 301 – Peripheral vascular disorders 46 057
Amputation Any Diabetic code + CIE-9CM: 84.1,
84.10, 84.11, 84.14, 84.15, 84.17, 84.19
Low limb amputation secondary to diabetic foot 58 831
All diabetic hospitalisations ICD-10 codes
E10.9, E11.9, E12.9, E13.9, E14.9, E10.0, E10.1, E10.6, E10.7, E10.8, E11.0, E11.1, E11.6, E11.7, E11.8, E12.0, E12.1, E12.6, E12.7, E12.8, E13.0, E13.1, E13.6, E13.7,
E13.8, E14.0, E14.1, E14.6, E14.7, E14.8, E10.5, E11.5, E12.5, E13.5, E14.5, E10.3, E11.3, E12.3, E13.3, E14.3, E10.2, E11.2, E12.2, E13.2, E14.2, E10.4, E11.4, E12.4,
E13.4, E14.4
Source: Lugo-Palacios and Cairns [2]
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complication in the current year oscillates around 15 %
of the total. Only 3 % of diabetic neuropathy hospitali-
sations per year fall into this classification. Whereas,
multiple discharges in the same year are more impor-
tant in the case of kidney failure and retinopathy,
accounting for more than 20 % of hospitalisations in
some years.
Hospitalisations of patients that have been admitted at
least once for the same condition in previous years in-
creased their share throughout the period, but this in-
crease is not the same for all conditions. The most
important increment in the share of these multiple dis-
charges is observed in amputations which grew 46 %
from 10.1 % of amputations in 2008 to 14.7 % in 2014;
neuropathy was the complication whose multiple dis-
charges share increased the least (4.5 %). An increase in
multiple discharges reflects the fact that the probability
of having at least one hospitalisation in previous years
increases over time and, of course, an unknown
proportion of patients in the first year of analysis (2007)
were hospitalised in previous years; nevertheless, these
data give an indication of the extent to which diabetes is
being controlled over time.
Financial burden
Tables 3 and 4 show the estimated financial costs of hos-
pitalisations resulting from diabetic complications. These
costs increased by 8.4 % in real terms between 2007 and
2014. However, when measured as cost per IMSS affili-
ate, the estimated costs decreased by 11.3 % from
MXN$41.5 in 2007 to MXN$36.8 in 2014. The hospital-
isation costs of kidney failure, retinopathy and neur-
opathy decreased by 7, 9 and 8 %, respectively, while
those for diabetic foot and amputations increased by
more than 25 %. Despite these changes, kidney failure
remains the most important cause of preventable hospi-
talisation costs, accounting for 43 % of costs in 2014.
Table 2 Diabetic preventable hospitalisations in IMSS 2007–2014. Hospital discharges
Hospital discharges
2007 2008 2009 2010 2011 2012 2013 2014 Total
Kidney failure 15 369 16 744 14 635 14 893 15 400 15 925 14 977 14 353 122 296
Retinopathy 2 393 1 554 1 690 1 597 1 764 1 446 1 824 2 178 14 446
Neuropathy 720 690 683 650 691 602 650 660 5 346
Diabetic foot 14 000 14 608 14 697 16 433 16 816 16 818 17 070 17 759 128 201
Amputation 6 001 6 285 6 226 6 646 6 571 6 560 6 889 7 510 52 688
TOTAL 38 483 39 881 37 931 40 219 41 242 41 351 41 410 42 460 322 977
Multiple discharges for the same complication in the same year
2007 2008 2009 2010 2011 2012 2013 2014 Total
Kidney failure 2 854 3 369 2 521 2 678 2 865 2 959 2 772 2 685 22 703
Retinopathy 376 249 148 124 256 274 373 461 2 261
Neuropathy 22 23 15 22 13 15 16 17 143
Diabetic foot 1 939 2 013 2 035 2 294 2 425 2 420 2 557 2 573 18 256
Amputation 422 453 433 457 455 462 472 546 3 700
TOTAL 5 613 6 107 5 152 5 575 6 014 6 130 6 190 6 282 47 063
At least one admission for the same condition in previous years (plus multiple discharges in the same year)
2007 2008 2009 2010 2011 2012 2013 2014 Total
Kidney failure - 4 094 3 493 3 709 3 924 4 151 3 937 3 822 27 130
Retinopathy - 323 237 255 350 363 474 575 2 577
Neuropathy - 30 21 34 21 22 26 30 184
Diabetic foot - 2 752 3 060 3 686 4 029 4 166 4 394 4 622 26 709
Amputation - 632 724 851 876 914 987 1 104 6 088
TOTAL - 7 831 7 535 8 535 9 200 9 616 9 818 10 153 62 688
Number of IMSS affiliates per year
2007 2008 2009 2010 2011 2012 2013 2014
48 650 488 48 909 706 49 134 310 52 310 086 54 906 396 57 475 897 59 511 963 59 487 144
Source: Authors using data from IMSS (2015) and INEGI (2015) [16, 25]
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Health burden
The estimated DALYs associated with diabetic complica-
tions are presented in Table 5. Overall, as opposed to
the financial costs, DALYs decreased by 13.6 % from
2007 to 2014; however, in the last 3 years of the period,
they increased slightly by 3.4 %. The latter is explained
mainly by the 44 % increase observed in the DALYs as-
sociated with diabetic retinopathy after 2012.
During the whole study period, the DALYs associated
with kidney failure have always represented more than
50 % of the estimated total, reaching a peak of 62 %
in 2008.
When disaggregating DALYs into YLD and YLL (not
shown, but available upon request), the gap that grew
in 2007–2008 between the YLD associated with kidney
failure and those associated with retinopathy, following
the important drop in retinopathy admissions, nar-
rowed in recent years due to a sustained fall in kidney
failure YLDs and a steep increase in retinopathy YLDs
during 2012–2014. Amputation YLDs as a share of
total YLDs rose in successive years from 13 % in 2007
to 20 % in 2014.
Figure 1 (exhibits a and b) presents the financial and
health burden over time for each of the complications. It
shows that the financial and health burdens for kidney
failure have decreased throughout the period. While the
gap between the kidney failure health burden and that of
the other diabetic complications is still considerable, the
difference in the financial burden has importantly nar-
rowed due to the increase in both the absolute and rela-
tive importance of the diabetic foot and amputation
hospitalisation costs.
Discussion
This study identifies potentially preventable hospitalisa-
tions due to five diabetic complications (kidney failure,
retinopathy, neuropathy, diabetic foot and amputation)
from 2007 to 2014 and estimates the associated financial
and health burden. These hospitalisations increased by
10.3 % during the study period and the estimated finan-
cial costs of hospitalisations resulting from diabetic com-
plications increased by 8.4 % in real terms, reaching
MXN$2,186 million in 2014; when measured as costs
per IMSS affiliate the estimated costs decreased by
11.3 % from MXN$41.5 in 2007 to MXN$36.8 in 2014.
The total health burden, expressed in DALYs associated
with these conditions, decreased by 13.6 %.
Table 6 compares the findings of this paper with the
burden estimated for the general hospitals run by the
state health ministries (SHMs) [2]; the financial and the
health burden of preventable diabetic hospitalisations in
IMSS per capita in 2011 is higher by 82 and 45 %, re-
spectively. The difference in health burden may be
greater since the present study avoids double counting
DALYs when patients are admitted more than once for
the same cause and/or if patients died during their
hospitalisations in a given year, unlike the data from
the SHMs.
Differences between IMSS and the SHMs in the trend
of the burden of diabetic complications arise for two
main reasons. First, increases in the estimated preva-
lence, diagnosis, and treatment of diabetes are largely
attributable to the expansion of health insurance
pushing preventable hospitalisations up among previ-
ously uninsured whose poorly controlled/unknown
diabetes hindered the ability of primary care to avoid
hospitalisations [7, 24]. While SHMs had to face the
increase in the demand for health services following
this health insurance expansion, IMSS coverage has
remained relatively stable during the last decade [25].
Second, as Arredondo and De Icaza (2011) show, and
consistent with the findings presented here, IMSS
costs per diabetic patient treated are 80 % higher
mainly due to differences in case management proto-
cols, in productivity standards, in quality standards
and in the cost of inputs [26].
Table 4 Financial costs per IMSS affiliated (2011 MXN)
2007 2008 2009 2010 2011 2012 2013 2014
Kidney failure 20.8 22.6 19.7 18.8 18.5 18.3 16.6 15.9
Retinopathy 1.0 0.7 0.7 0.6 0.7 0.5 0.6 0.8
Neuropathy 0.5 0.5 0.5 0.4 0.4 0.4 0.4 0.4
Diabetic foot 12.3 12.8 12.8 13.4 13.1 12.5 12.3 12.8
Amputation 6.7 7.0 6.9 6.9 6.5 6.2 6.3 6.9
Total 41.5 43.6 40.6 40.2 39.3 37.9 36.2 36.8
Source: Authors using data from IMSS (2015) [16]
Table 3 Financial ACSH cost (2011 Million MXN)
2007 2008 2009 2010 2011 2012 2013 2014
Kidney failure 1 014.32 1 105.08 965.86 982.87 1 016.34 1 051.01 988.41 947.21
Retinopathy 50.71 32.93 35.81 33.84 37.38 30.64 38.65 46.16
Neuropathy 25.07 24.03 23.78 22.63 24.06 20.96 22.63 22.98
Diabetic foot 598.81 624.83 628.61 702.85 719.24 719.34 730.09 759.55
Amputation 327.87 343.39 340.15 363.09 359.00 358.41 376.37 410.29
TOTAL 2 016.78 2 130.26 1 994.22 2 105.29 2 156.03 2 180.36 2 156.15 2 186.18
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Apart from differences in the magnitude of the bur-
dens, another important difference is the trend that
each burden follows. In the case of SHMs, the rate of
diabetic complications, the financial burden, the finan-
cial burden per person with no social security, and the
health burden increased over the study period, while
for IMSS only the financial burden from diabetic foot
and amputation hospitalisations increased. The finan-
cial burden of diabetic foot and amputation increases
among patient groups in IMSS and SHMs. Exhibits c
and d in Fig. 1 show the comparison of the financial
burden per target population and the total health bur-
den of IMSS and of SHMs for 2007–2011. Both IMSS
burdens show a decreasing trend while the opposite is
observed for the SHMs.
All major complications of diabetes can be prevented
or delayed by good control of blood glucose, blood pres-
sure and cholesterol levels [1]. This requires the patient
to be well-informed regarding management of their con-
dition, as well as access to insulin, oral medications and
monitoring equipment. People with diabetes should be
supported by a well-educated health work force and
health systems that provide regular blood tests and eye
and foot examinations [1]. In addition, it should be
noted that, paradoxically, as people with diabetes live
longer they become more likely to suffer diabetic compli-
cations; therefore, it is important to develop new strategies
that can prevent the onset or progression of diabetic com-
plications [27]. During recent years, IMSS has imple-
mented a number of strategies to improve the control of
chronic conditions among its beneficiaries, especially
those with diabetes. Evaluation of these strategies is
beyond the scope of this paper; however, the evidence pre-
sented indicates that the rate of hospitalisation due to
complications of diabetes per IMSS affiliate, the financial
burden per IMSS affiliate, and the associated health
Table 5 Disability Adjusted Life Years (DALYs) associated with diabetic preventable hospitalisations. IMSS 2007–2014
Complications 2007 2008 2009 2010 2011 2012 2013 2014
Kidney failure 67 139 67 341 60 409 57 960 60 578 61 261 58 265 54 683
Retinopathy 33 931 20 350 23 777 22 021 23 701 18 343 22 509 26 481
Neuropathy 2 300 2 317 2 278 2 167 2 230 1 950 2 211 2 117
Diabetic foot 4 173 5 017 5 459 5 869 4 839 4 952 4 005 4 611
Amputation 12 508 12 917 13 052 13 561 13 209 13 813 14 634 15 796
TOTAL 120 051 107 941 104 975 101 578 104 557 100 320 101 625 103 688
Source: Authors using data from IMSS (2015)
Exhibit a) Exhibit b)
Exhibit c) Exhibit d)
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burden has decreased during the period studied. Since the
absolute financial burden increased more than 8 %, there
are likely to be opportunities to shift resources from ex-
pensive hospital care to more cost-effective primary care
interventions; especially since the hospitalisation costs for
diabetic foot and amputations are increasing, and these
are avoidable with good diabetes management, specifically,
with regular foot examination [1].
Improving the quality of and effective access to public
primary care services is crucial to ensure appropriate
diabetes management as it is worrying that one in eight
users state that they would avoid these services in the
future mainly because of unacceptable waiting times,
mistreatment or no improvement in their condition [28].
Furthermore, it is necessary to tackle misconceptions
that primary care is basic health care, health care for the
poor or rural health care, among the sector of the popu-
lation that still prefers hospital over primary care [29].
The fact that the total health burden decreases while
both the number of preventable hospitalisations and the
total financial burden increase is due to the way in which
DALYs are computed. The contribution of a patient to the
DALYs count of a specific condition only takes into ac-
count the first hospitalisation of the patient for the same
cause over the period in order to avoid double-counting.
Therefore, multiple admissions of the same patient for the
same cause do not contribute to the health burden. How-
ever, every hospitalisation, whether or not it is the first or
a subsequent one, represents a cost to the hospital. Fur-
thermore, the importance of avoiding double-counting of
the health burden associated with multiple discharges for
the same condition over time is clear when 24 % of total
hospital discharges due to diabetic complications in 2014
do not contribute to the DALYs count.
This analysis is subject to a limitation present in early
work [2]. Since the severity of the condition for which
patients were hospitalised is not recorded, and there is a
lack of disability weights for different severity levels of
kidney failure and retinopathy, all kidney failure and ret-
inopathy admissions were assumed to have the same se-
verity level: stage IV and blindness, respectively. This
assumption causes an overestimation of the associated
DALYs and should be taken as the upper bound of the
health burden associated with preventable diabetic hos-
pitalisations. As opposed to Lugo-Palacios and Cairns
[2], by tracking multiple discharges from the same pa-
tient over the study period, the present paper avoids the
double-counting of DALYs when patients are admitted
more than once for the same cause throughout the
period and/or if patients died in any of their hospitalisa-
tions in a given year. A second limitation is that both di-
mensions of the burden associated with preventable
diabetic hospitalisations only consider affiliates receiving
care in IMSS hospitals; however, affiliates seeking care
elsewhere or not seeking care at all are not taken into
account (around 30 % of IMSS affiliates seek primary
care from the private sector [29]). In addition, IMSS-
DRG costs do not necessarily represent what IMSS hos-
pitals are actually spending on each treatment, but ra-
ther are used as a benchmark, and IMSS-DRG costs do
not consider rural-urban nor big-small city price differ-
entials [2]. Nevertheless, these costs are the most robust
hospital cost data available for IMSS.
Conclusions
Timely and effective primary care services that prevent
the development or the exacerbation of the condition
can reduce the burden of preventable hospitalisations.
The resources used to treat avoidable hospitalisations
could, in principle, be used to fund more and better pri-
mary care services. However, more evidence is required
concerning which strategies are best for preventing hos-
pitalisations and how much of the burden could be pre-
vented by better primary care. This study might be seen
as setting an upper limit to the potential benefit from
improving primary care. IMSS is currently integrating
primary care and hospital data at the patient level. Con-
sequently, it should be possible to obtain a better under-
standing of the scope for primary care to prevent
hospitalisations. The improvement of record linkage
among levels of care and among all Mexican health care
institutions through the patient clinical-electronic file is
crucial in the design of a new integrated primary care
system that could provide opportunities to reduce the fi-
nancial and health burden of diabetic complications.
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